

European Haemophilia Consortium

Round Table on 'Usage and Measurement of Extended Half-Life Coagulation Factors and Non-Substitutional Therapies'

Tuesday, 28 November, 13:00 – 16:00

Sofitel Hotel EU

Brussels, Belgium

Speaker biographies

Michael Makris

Director, Sheffield Haemophilia and Thrombosis Centre

Professor Michael Makris is Director of the Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK. He trained in Medicine and Haematology at the Universities of Oxford, London and Sheffield in the UK. He is Professor of haemostasis and thrombosis at the University of Sheffield and since 1994, he has been an honorary consultant haematologist at The Sheffield Teaching Hospitals NHS Trust.

Professor Makris' research interests include the monitoring of adverse events in haemophilia, hepatitis C in haemophilia, thrombin generation assays in bleeding and thrombotic disorders and the genetics of inherited platelet disorders. Professor Makris is one of two editors of the journal *Haemophilia*. He is on the Editorial Board of the journals *British Journal of Haematology*, *Blood Transfusion* and the *Journal of Thrombosis and Haemostasis*.

Professor Makris is a member of the Medical Advisory Group (MAG) of the European Haemophilia Consortium (EHC), providing medical and scientific expertise in areas related to the comprehensive care of haemophilia and other rare bleeding disorders. He is also vice president of the European Association for Haemophilia and Allied Disorders (EAHAD).

Roger Schutgens

Haematologist and epidemiologist at the University Medical Centre (UMC) in Utrecht

Professor Schutgens is a haematologist and epidemiologist at the University Medical Centre (UMC) in Utrecht, Netherlands, as well as head of department at the Van Creveldkliniek – one of the largest treatment centres in the Netherlands for children and adults with haemophilia and other rare bleeding disorders.

Since December of 2016, Roger Schutgens is also a Professor of thrombosis at UMC. He chairs the Blood Transfusion Committee and the Anticoagulation Committee and is a member of the European Working Group (ADVANCE) for older haemophiliacs.

Annette Bowyer

Section lead for Haemophilia Assays in the Department of Coagulation at Sheffield Haemophilia and Thrombosis Centre

Annette Bowyer is the Section Lead for Haemophilia Assays in the Department of Coagulation at Sheffield Haemophilia and Thrombosis Centre. The centre is a designated International Haemophilia Training Centre by the World Federation of Haemophilia. Dr Bowyer was awarded her PhD in Cardiovascular Science from the University of Sheffield with a thesis focusing on the laboratory diagnosis of mild Haemophilia A. She has more than 15 years of experience in the diagnosis and monitoring of bleeding disorders with a current focus on laboratory issues surrounding extended half-life treatment products for haemophilia. Dr Bowyer is a fellow of the Institute of Biomedical Science and member of the International Society on Thrombosis and Haemostasis and the World Federation of Haemophilia.

Caroline Voltz-Girolt

EMA Product Lead in Oncology, Haematology and Diagnostics at European Medicines Agency

Mrs Caroline Voltz-Girolt has been working for the European Medicines Agency (EMA) for the past 9 years, where she has held different positions and has worked on several projects. Prior to joining the EMA, she worked in the pharmaceutical industry. She is currently working as an EMA Product Lead in the Oncology, Haematology and Diagnostics Office, where she is in charge of the secretariat of the Blood Products Working Party. She also has specific expertise in Advanced Therapy Medicinal Products (ATMPs) and is a member of the Innovation Task Force and the Classification of Post-Authorisation Studies (CPAS). She coordinated the 2015 revision of EMA's good pharmacovigilance practices (GVP) Risk Management Plan template.

Niamh O'Connell

St James Hospital, Consultant Haematologist

Dr Niamh O'Connell is a Consultant Haematologist at the National Coagulation Centre (NCC), St. James's Hospital, Dublin, Ireland and joined the Irish National Coagulation Centre (NCC) in 2010 after specialist training in Haemostasis and Thrombosis in Ireland and the UK.

The NCC is the lead comprehensive care centre in Ireland and provides a hub of clinical services, research, training and education on a national basis. The NCC, in partnership with the Irish Haemophilia Society, is committed to delivering high quality and safe health care and to promoting healthy and successful living for people and their families living with haemophilia and other coagulation disorders.

Her research interests include clinical trials in novel therapies for haemophilia, clinical outcomes in haemophilia and application of information technology solutions in the management of haemophilia.

Deborah Morrison

Senior Scientific Adviser, NICE Scientific Advice

Dr Deborah Morrison leads on a number of strategic initiatives within the scientific advice team. She holds an Honours Degree in Pharmacy and a Clinical Diploma in Clinical Pharmacy. Previously, Deborah was responsible for developing a series of combined clinical and commissioning roles within Cambridgeshire Primary Care Trust and NHS Cambridgeshire CCG. She led on the economic evaluation, assessment and prioritisation of new drugs and therapies for the local and regional health economies. She was Lead Pharmacist for the Anglia Cancer Network and Lead Pharmacist for the former Public Health Network associated with the PCT.

Deborah has also worked within a hospital foundation trust to optimise its economic evaluation and implementation of drugs and devices and as a professional adviser to various healthcare consulting companies.

She has an MSc in Economic Evaluation in Healthcare and remains a registered Pharmacist.

Dr Radoslaw Kaczmarek

EHC Steering Committee Member

Dr Radoslaw (Radek) Kaczmarek is an assistant professor at Hirszfeld Institute of Immunology and Experimental Therapy in Wroclaw, Poland. His research interests involve glycobiology and transfusion medicine.

Radek is a board member of the Polish Haemophilia Society and a member of the European Haemophilia Consortium (EHC) Steering Committee. He has been a volunteer with both organisations and the World Federation of Hemophilia for many years. Radek has been involved in many advocacy efforts for improvement of haemophilia care both in his home country and at the European level, representing the EHC *vis-à-vis* the European Medicines Agency and other relevant institutions.

Radek has severe haemophilia A.

Cedric Hermans

Associate Head of Unit, Haemostasis and Thrombosis Unit

Professor Cedric Hermans completed his medical training and specialisation in general internal medicine at Catholic University of Louvain, Belgium. He obtained his PhD in Biomedical Sciences, specialising in toxicology, in 1999. In 2000, he embarked on a one-year fellowship at the Haemophilia Centre and Haemostasis Unit of the Royal Free Hospital, London, UK.

He was appointed associate professor at the Medical School of the Catholic University of Louvain in 2003 and full professor in 2012. He is currently heading the Haemostasis and Thrombosis Unit and the Haemophilia Centre of the Saint-Luc University Hospital, Brussels and is Vice Dean of the Medical School of the Catholic University of Louvain.

Dr Hermans has published over 180 original articles in international journals and is a member of several scientific societies and international advisory boards. He is currently President of the European Association for Haemophilia and Allied Disorders (EAHAD) and was recently appointed as member of the Board of Directors of the World Federation of Haemophilia. His main research interests lie in the area of haemostasis and thrombosis, especially clinical studies on the treatment of haemophilia, new anticoagulants, and the management of thrombosis
